This report examines the impact of the COVID-19 pandemic on venture capital deals for biopharmaceutical companies. This analysis is critical to understanding how the outbreak of COVID-19 impacted investments and how those VC deal trends may impact current and future venture capital investments.
Scope
This 32-page report gives important, expert insight you won’t find in any other source. 11 tables and 9 figures throughout the report illustrate major points and trends. This report is required reading for:
• Investors that want to understand how COVID-19 has impacted VC deals in the biopharmaceutical industry as well as identifying companies that may be due for a round of financing in upcoming months
• Companies that are due to raise venture capital in the near future and need to consider 2020 VC trends into their capital raising strategies.
• Large pharma companies with investment groups or BD teams looking for partnership opportunities where companies may be in need of financing with changing VC trends during the COVID-19 pandemic.
Reasons to buy
Monthly trends of VC deals by value and volume; including an analysis of monthly VC activity in China versus U.S. during the spread of the diease
Analyzes how COVID-19 has shifted investment trends by deal value, round, and therapeutic area
Assessment of investors activity level in biopharmaceutical VC deals prior to and during the COVID-19 pandemic
Identify biopharmaceutical companies that may be looking for rounds of financing and how they may be impacted by the shifted trends in VC investment
Companies mentioned
4d Molecular Therapeutics
Adlai Nortye Biopharma Co Ltd.
AIVITA Biomedical, Inc.
Akouos Inc
Alexandria Venture Investments
Aligos Therapeutics Inc
ALX Oncology Inc
Amal Therapeutics SA
Annexon, Inc
Ansun BioPharma Inc
Antiva Biosciences
Apexigen, Inc.
Aqualung Therapeutics Corp
ARCH Venture Partners LP
ARS Pharmaceuticals, Inc.
Ascentage Pharma group
Atomwise Inc.
Biopact Cellular Transport Inc
Blueberry Therapeutics Ltd.
Boxer Capital
BW Therapeutics LLC
Cadent Therapeutics
Carisma Therapeutics Inc.
Casdin Capital LLC
Casma Therapeutics, Inc.
Celsense Inc
CerFlux Inc
Chondrial Therapeutics LLC
Cormorant Asset Management LLC
Cowen Healthcare Investments
Decibel Therapeutics, Inc.
Deerfield Management
ElevateBio LLC
Emulate Inc.
EQRx Inc
Escient Pharmaceuticals, Inc.
Evox Therapeutics Ltd
Fidelity Management & Research
Foresite Capital Management LLC
Freeline Therapeutics
Galecto Biotech AB
Galera Therapeutics Inc
Generation Bio Corp
Heartseed Inc
Horama SA
Hotspot Therapeutics, Inc
Hoverink Biotechnologies Inc
ILiAD Biotechnologies, LLC
Immune-Onc Therapeutics, Inc.
Immunocore Ltd
Impact Therapeutics
InCarda Therapeutics, Inc.
InSightec Ltd
Intarcia Therapeutics Inc
Intensity Therapeutics, Inc.
iTeos Therapeutics SA
KAHR medical Ltd
Kaitai Capital
Kallyope Inc
Kleo Pharmaceuticals Inc
Ksq Therapeutics, Inc
Kymera Therapeutics LLC
Lilly Asia Ventures
Max Biopharma Inc
Medicxi Ventures (UK) LLP
Metacrine, Inc.
Minoryx Therapeutics
Modalis Therapeutics Corporation
Nanjing Legend Biotech Co Ltd
NBE-Therapeutics AG
Neuraly, Inc
Neurana Pharmaceuticals, Inc.
Neurotez Inc
NMD Pharma ApS
Nohla Therapeutics, Inc.
Novo Holdings AS
Oncoheroes Biosciences Inc
OncoResponse, Inc.
Orasis Pharmaceuticals
Orbimed Advisors LLC
Partner Therapeutics, Inc
Perceptive Advisors
Phylos Bioscience Inc
Pliant Therapeutics Inc
Polaris Partners LLC
Quentis Therapeutics, Inc.
RA Capital Management LLC
Rakuten Medical Inc
Rallybio, LLC
ReAlta Life Sciences Inc
Redmile Group LLC
Relay Therapeutics
RemeGen Ltd
Rgenix, Inc
Rheos Medicines, Inc.
Ripple therapeutics Corp
Rongchang Bio-Pharmaceutical Co., Ltd
Sen-Jam Pharmaceutical LLC
Senti Biosciences, Inc
Sirnaomics, Inc.
Slayback Pharma LLC
SQZ Biotech
StemBioSys Inc
Surveyor Capital Ltd
SutroVax Inc
Synthego Corporation
Tecnologia Regenerativa Qrem SL
Transcenta Holding Ltd
Vedanta Biosciences, Inc.
Velicept Therapeutics, Inc.
Vivo Capital LLC
Xilio Therapeutics Inc
XtalPi, Inc.
